Fig. 1: MTCH2 overexpression correlates with key clinical parameters of prostate cancer. | Cell Death & Disease

Fig. 1: MTCH2 overexpression correlates with key clinical parameters of prostate cancer.

From: Identification of mitochondrial carrier homolog 2 as an important therapeutic target of castration-resistant prostate cancer

Fig. 1

TCGA-PRAD cohort analysis compares the MTCH2 mRNA transcript levels between prostate cancer tissue (“Tumor”) and normal tissue (“Normal”) from the described patients (A–G). Correlation analysis identified co-expressed genes (CEGs) with MTCH2 from TCGA-PRAD samples (H). Differential expression analysis was performed on TCGA-PRAD samples divided into high- and low-MTCH2 expression groups to identify differentially expressed genes (DEGs) (I). The intersection of CEGs and DEGs resulted in 128 common genes (J). The WikPathway pathway enrichment analysis of these 128 common genes revealed significant associations of MTCH2 with multiple pathways (K). “TPM” indicates transcripts per million. *P < 0.05, **P < 0.01, and ***P < 0.001.

Back to article page